

威部门能够精诚合作,对比索洛尔、美托洛尔和卡维地洛进行以患者最大耐受能力作为个体化目标剂量的随机临床试验,来评价这几种药物对死亡率等重大临床事件的影响以及相对效益^[9, 17]。这类试验将能够更好地指导临床医师正确使用 β 受体阻滞剂,也能够给心力衰竭患者带来更大的益处。

参考文献

- 1 CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. *Lancet*, 1999, 353: 9-13.
- 2 MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*, 1999, 353: 2001-2007.
- 3 Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med*, 2001, 344:1651-1658.
- 4 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 慢性收缩性心力衰竭治疗建议. *中华心血管病杂志*, 2002, 30:7-23.
- 5 Packer M, Cohn JN, Abraham WT, et al. Consensus recommendations for management of chronic heart failure. *Am J Cardiol*, 1999, 83:1A-38A.
- 6 Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. *Eur Heart J*, 2001, 22:1527-1560.
- 7 Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. *Circulation*, 1996, 94:2807-2816.
- 8 Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure. Analysis of the experience in Metoprolol CR/XL Randomized International Trial in Chronic Heart Failure (MERIT-HF). *J Am Coll Cardiol*, 2002, 40:491-498.
- 9 Simon T, Mary-Krause M, Furck-Brentano C, et al. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). *Eur Heart J*, 2003, 24:552-559.
- 10 Poole-Wilson PA, Cleland JGF, Lenarda AD, et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. *Eur J Heart Fail*, 2002, 4:321-329.
- 11 Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet*, 2003, 362:7-13.
- 12 Wikstrand J, Fagerberg B, Goldstein S, et al. COMET: a proposed mechanism of action to explain the results and concerns about dose (letter). *Lancet*, 2003, 362:1076-1077.
- 13 Bristow MR. β -adrenergic receptor blockade in chronic heart failure. *Circulation*, 2000, 101:558-569.
- 14 Kukin ML, Mannino MM, Freudenberger RS, et al. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. *J Am Coll Cardiol*, 2000, 35:45-50.
- 15 Andersson B, Aberg J, Lindelow B, et al. Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure. *J Cardiac Fail*, 2001, 7:311-317.
- 16 Wikstrand J, Andersson B, Kendall MJ, et al. Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure. *J Cardiovasc Pharmacol*, 2003, 41:151-157.
- 17 Dargie HJ. Beta-blockers in heart failure (commentary). *Lancet*, 2003, 362:2-3.

· 消 息 ·

《中国心血管病研究杂志》征稿启事

《中国心血管病研究杂志》为国家新闻出版总署批准、国家卫生部主管、中国医师协会主办的全国性医学学术期刊。本刊于2003年5月创刊,国内外公开发行。ISSN 1672-5301, CN 11-5122/R, 月刊, 大16开本, 80页, 10元/期。全国各地邮局发行, 邮发代号为80-123。以从事心血管病预防、医疗和科研的医师和学者为读者对象, 以报道心血管病领域的科研成果和临床心血管病内、外科诊疗经验为主要内容, 突出科学性、先进性、可读性和实用性。坚持普及与提高相结合的方针, 反映我国心血管病临床、科研工作的重大进展, 促进心血管病学科的学术交流。主要栏目有: 专家评述、专家讲座、临床研究、基础研究、实验研究、误诊误治、综述、药械警戒等。欢迎广大读者订阅、投稿。

投稿请寄: 北京市朝阳区西坝河南里29号《中国心血管病研究杂志》编辑部, 邮编: 100028; 电话: 010-84541195/64667755-2299; E-mail: mtyx@heinfo.net; http://www.ok120.com